ClinicalTrials.gg
RecruitingNCT05481502PIONEERUpdated Nov 6, 2026

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

An interventional study of Tumor biopsy and Blood sample in Solid Tumor, Adult, Solid Tumor, Childhood and Hematologic Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 1 site in France. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Nov 6, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Planned enrollment
36th of 107
160 · median 106
Started
2022
with 9 others
No phase
29 of 142
12 open now
Primary completion
2027-07
later than 28 of 57 live
Registered
103rd of 142
by date

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 36th largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2022, is one of 29 with no phase, reaches primary completion later than 28 of the 57 other live ones, and was the 103rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.

The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.

03

Conditions studied

  • Solid Tumor, Adult
  • Solid Tumor, Childhood
  • Hematologic Cancer
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient affiliated to a social security regimen
  • Tumor lesion accessible to core
  • Patient who is fully informed, able to comply with the protocol and who signed the
  • Pediatric patients > than 2 years old can be included
  • No restriction about the (ECOG) status

Exclusion criteria

Exclusion Criteria:

  • Coagulation abnormality prohibiting a (but patients can still give their consent for blood and bone marrow samples).
  • Tumor lesion not accessible to core biopsies.
  • Pregnant or nursing women cannot participate in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Patients receiving advanced therapy medicinal products

    Procedure: Tumor biopsy · Procedure: Blood sample · Procedure: Bone marrow sample

Interventions

  • ProcedureTumor biopsy

    3 biopsies will be collected: at baseline, at day+15 and optionally at relapse

  • ProcedureBlood sample

    7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse

  • ProcedureBone marrow sample

    If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled

06

What researchers measure

Primary outcomes

  1. Comparison of frequency, phenotype and transcriptional profile of the different immune subsets in the tumor following adoptive cell therapy infusion using spectral flow cytometry and RNA sequencing

    Time frame: 3 months following ACT

Secondary outcomes

  1. Objective Response

    Defined by RECIST 1.1 score for lymphoma and solid tumors

    Time frame: 3 months following ACT

  2. Progression-free survival

    Defined as the time between the adoptive cell therapy and progression, or death whatever the cause, whichever occurs first.

    Time frame: 5 years after first ACT infusion

  3. Overall survival

    Defined as the time between the adoptive cell therapy injection and death whatever the cause

    Time frame: 5 years after first ACT infusion

  4. Safety of biopsies procedures (when applicable) graded according to CTCAE v5.0

    Time frame: From enrollment to 30 days after the last sample

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jul 2027, 60 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 60 months is above that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Aug 1, 2022
StartActual
Jun 8, 2022
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Gustave Roussy Cancer Campus Grand Paris · Villejuif, France
Show 1 removed
  • Gustave Roussy Cancer Campus Grand Paris · Villejuif, France
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed
    Show site
    • Gustave Roussy Cancer Campus Grand Paris · Villejuif, France
    Show 1 removed
    • Gustave Roussy Cancer Campus Grand Paris · Villejuif, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05481502
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Jun 8, 2022
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Camille BIGENWALD, MD
Contact
camille.bigenwald@gustaveroussy.fr
+33 (0)1 42 11 42 29
Cristina CASTILLA LLORENTE, MD
Contact
cristina.castilla-llorente@gustaveroussy.fr
+33 (0)1 42 11 42 39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion